Remove Communication Remove FDA Remove Packaging
article thumbnail

Independent Pharmacists’ Unique Role During Disaster Management Efforts

Drug Topics

Similar to Phillips’ idea of planning ahead, the FDA also has detailed provisions for patients to take during power outages, floods, or other events that compromise their ability to manage their medications. “An Taking precautions for storing medications and supplies is key to being prepared,” the FDA wrote. Innov Pharm. 2023;8(1):25.

article thumbnail

FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects the elderly. In February 2025, the FDA accepted Dupixent’s supplemental biologics licence application (sBLA) for priority review.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA issues draft guidance on alternative tools for facility assessments

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has published draft guidance on how it intends to use alternative tools for assessing drug manufacturing facilities identified in pending marketing applications. Fundamentally, this approach will establish whether facilities meet applicable requirements for FDA approval and licensure decisions.

FDA 105
article thumbnail

More on the Impact of the FDA RIFs: How Information Disclosure will Start FOIA-lling Behind

The FDA Law Blog

Food and Drug Administration (FDA) is already having ripple effects not just internally, but across the broader regulatory and life sciences communities and the public at large. However, not all information contained in FDA records is disclosable. However, not all information contained in FDA records is disclosable.

FDA 59
article thumbnail

MSD receives FDA approval for Enflonsia to prevent RSV

Pharmaceutical Technology

MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Can pharma tariffs “Make America Manufacture Again”? Credit: MargJohnsonVA/Shutterstock.

FDA 52
article thumbnail

FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia

Pharmaceutical Technology

YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). Credit: aipicte/Shutterstock. Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

FDA 52
article thumbnail

10 Innovative Trends in Pharma Marketing: Strategies for Industry Success in 2025

Pharma Marketing Network

Companies are investing heavily in digital tools to streamline communication and build stronger connections. Strategies like storytelling, personalized educational content, and two-way communication channels create trust and build loyalty. Patient-Centric Marketing Patients want to feel heard.